Terms: = Skin cancer AND CTLA4, ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12 AND Treatment
1207 results:
1. Case report: Is severe toxicity the price to pay for high sensitivity to checkpoint inhibitors immunotherapy in desmoplastic melanoma?
Squicciarini T; Villani R; Apollonio B; Fucci L; Zambetti M; Rossini M; Pinto R; Tommasi S; De Roma I; Strippoli S; Guida M
Front Immunol; 2024; 15():1369531. PubMed ID: 38799429
[TBL] [Abstract] [Full Text] [Related]
2. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
[TBL] [Abstract] [Full Text] [Related]
3. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors' perspective.
Kähler KC; Gutzmer R; Angela Y; Livingstone E; Lodde G; Meiss F; Rafei-Shamsabadi DA; Weyer-Fahlbusch SS; Nashan D; Loquai C; Hassel JC; Sachse MMM; Maul LV; Heinzerling L; Heppt MV; Colapietro C; Rusch J; Blome C
J Cancer Res Clin Oncol; 2024 May; 150(5):252. PubMed ID: 38743104
[TBL] [Abstract] [Full Text] [Related]
4. Molecular patterns of resistance to immune checkpoint blockade in melanoma.
Lauss M; Phung B; Borch TH; Harbst K; Kaminska K; Ebbesson A; Hedenfalk I; Yuan J; Nielsen K; Ingvar C; Carneiro A; Isaksson K; Pietras K; Svane IM; Donia M; Jönsson G
Nat Commun; 2024 Apr; 15(1):3075. PubMed ID: 38594286
[TBL] [Abstract] [Full Text] [Related]
5. Therapeutic inhibition of monocyte recruitment prevents checkpoint inhibitor-induced hepatitis.
Gudd CLC; Mitchell E; Atkinson SR; Mawhin MA; Turajlic S; Larkin J; Thursz MR; Goldin RD; Powell N; Antoniades CG; Woollard KJ; Possamai LA; Triantafyllou E
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580334
[TBL] [Abstract] [Full Text] [Related]
6. Severe autoimmune hemolytic anemia following immunotherapy with checkpoint inhibitors in two patients with metastatic melanoma: a case report.
Fetter T; Fietz S; Bertlich M; Braegelmann C; de Vos-Hillebrand L; Wenzel J; Heine A; Landsberg J; Jansen P
Front Immunol; 2024; 15():1342845. PubMed ID: 38571955
[TBL] [Abstract] [Full Text] [Related]
7. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma.
Su DG; Schoenfeld DA; Ibrahim W; Cabrejo R; Djureinovic D; Baumann R; Rimm DL; Khan SA; Halaban R; Kluger HM; Olino K; Galan A; Clune J
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519058
[TBL] [Abstract] [Full Text] [Related]
8. Linear IgA bullous dermatosis associated with immunotherapy.
Momin B; Nguyen TF; Glade D; Messer A
Dermatol Online J; 2023 Dec; 29(6):. PubMed ID: 38478666
[TBL] [Abstract] [Full Text] [Related]
9. Tumor-infiltrating macrophage associated lncRNA signature in cutaneous melanoma: implications for diagnosis, prognosis, and immunotherapy.
Wan Q; Deng Y; Wei R; Ma K; Tang J; Deng YP
Aging (Albany NY); 2024 Mar; 16(5):4518-4540. PubMed ID: 38475660
[TBL] [Abstract] [Full Text] [Related]
10. Immune checkpoint inhibitors associated cardiovascular immune-related adverse events.
Jo W; Won T; Daoud A; Čiháková D
Front Immunol; 2024; 15():1340373. PubMed ID: 38375475
[TBL] [Abstract] [Full Text] [Related]
11. Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma.
Haugh A; Daud AI
Am J Clin Dermatol; 2024 May; 25(3):407-419. PubMed ID: 38329690
[TBL] [Abstract] [Full Text] [Related]
12. Relevance of detection of RAF fusion transcripts in pan-negative melanoma in routine practice.
Delzenne G; Boileau M; Jamme P; Farchi O; Mortier L
Melanoma Res; 2024 Apr; 34(2):182-185. PubMed ID: 38329225
[TBL] [Abstract] [Full Text] [Related]
13. Effects of ctla-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma.
de Joode K; Mora AR; van Schaik RHN; Zippelius A; van der Veldt A; Gerard CL; Läubli H; Michielin O; von Moos R; Joerger M; Levesque MP; Aeppli S; Mangana J; Mangas C; Trost N; Meyer S; Parvex SL; Mathijssen R; Metaxas Y
J Immunother; 2024 Jun; 47(5):190-194. PubMed ID: 38318726
[TBL] [Abstract] [Full Text] [Related]
14. Immunotherapy for non-small cell lung cancer.
Kagamu H
Respir Investig; 2024 Mar; 62(2):307-312. PubMed ID: 38310751
[TBL] [Abstract] [Full Text] [Related]
15. The fatty acid-related gene signature stratifies poor prognosis patients and characterizes TIME in cutaneous melanoma.
Hua S; Wang W; Yao Z; Gu J; Zhang H; Zhu J; Xie Z; Jiang H
J Cancer Res Clin Oncol; 2024 Jan; 150(2):40. PubMed ID: 38279987
[TBL] [Abstract] [Full Text] [Related]
16. A critical review on the ecotoxicity of heavy metal on multispecies in global context: A bibliometric analysis.
Gogoi B; Acharjee SA; Bharali P; Sorhie V; Walling B; Alemtoshi
Environ Res; 2024 May; 248():118280. PubMed ID: 38272294
[TBL] [Abstract] [Full Text] [Related]
17. Preconditioning with immunogenic cell death-inducing treatments for subsequent immunotherapy.
Pan H; Liu P; Kroemer G; Kepp O
Int Rev Cell Mol Biol; 2024; 382():279-294. PubMed ID: 38225106
[TBL] [Abstract] [Full Text] [Related]
18. Systematic Multiomic Analysis of
Kang JY; Yang J; Lee H; Park S; Gil M; Kim KE
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203530
[TBL] [Abstract] [Full Text] [Related]
19. Single agent vs combination immunotherapy in advanced melanoma: a review of the evidence.
Benhima N; Belbaraka R; Langouo Fontsa MD
Curr Opin Oncol; 2024 Mar; 36(2):69-73. PubMed ID: 38193381
[TBL] [Abstract] [Full Text] [Related]
20. CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.
Zeng S; Chen XI; Yi Q; Thakur A; Yang H; Yan Y; Liu S
Oncol Res; 2023; 32(2):261-272. PubMed ID: 38186580
[TBL] [Abstract] [Full Text] [Related]
[Next]
